Becton Dickinson Stock Dives 1.81% Amid 100.16% Volume Spike to $670M Ranking 199th in Market Activity as FDA Submission Drives Volatility

Becton Dickinson (BDX) saw a 1.81% decline on July 31, 2025, despite a 100.16% surge in trading volume to $670 million, ranking 199th in market activity. The move followed the company’s submission of an FDA application for an at-home HPV testing kit, designed to streamline cervical cancer screening through self-collected swab samples. The test, which leverages automated robotics via the BD COR™ System, aims to detect more high-risk HPV strains than existing alternatives, addressing unmet demand highlighted by a Harris Poll survey showing 72% of U.S. women delay gynecology visits due to convenience concerns.

The FDA filing underscores BD’s strategic push into accessible diagnostics, aligning with evolving clinical guidelines. The Onclarity™ Assay, a key component, has been integrated into the American Society for Colposcopy and Cervical Pathology’s risk-based management framework, while self-collection methods are under review by the U.S. Preventive Services Task Force. The technology eliminates manual sample preparation, reducing labor costs and enhancing scalability for labs. However, regulatory approval timelines and market adoption rates remain critical uncertainties for near-term revenue impact.

A strategy of purchasing the top 500 high-volume stocks and holding for one day generated a 166.71% return from 2022 to July 30, 2025, outperforming the benchmark by 137.53%. This success highlights the role of liquidity and momentum in driving returns, particularly for stocks like BD that experience volume spikes tied to product announcements. The approach’s risk-managed execution and adaptability to market shifts further validate its effectiveness in capitalizing on short-term price movements linked to news-driven volatility.